Serum levels of interleukin-7 and interleukin-8 in head and neck squamous cell carcinoma

2014 ◽  
Vol 51 (3) ◽  
pp. 227 ◽  
Author(s):  
A Ghaderi ◽  
Z Mojtahedi ◽  
Y Taregh ◽  
Z Rafati ◽  
B Khademi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Serum Levels ◽  
Interleukin 8 ◽  
Neck Squamous Cell Carcinoma ◽  
Interleukin 7

Interleukin-8 Expression by Head and Neck Squamous Cell Carcinoma

1995 ◽  
Vol 121 (2) ◽  
pp. 202-209 ◽  
Author(s):  
R. F. Cohen ◽  
J. Contrino ◽  
J. D. Spiro ◽  
E. A. Mann ◽  
L. L. Chen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Interleukin 8 ◽  
Neck Squamous Cell Carcinoma

Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma

Oral Oncology ◽  
2013 ◽  
Vol 49 (8) ◽  
pp. 761-770 ◽  
Author(s):  
Rekha Gyanchandani ◽  
Daisuke Sano ◽  
Marcus V. Ortega Alves ◽  
Jonah D. Klein ◽  
Beth A. Knapick ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Interleukin 8 ◽  
Neck Squamous Cell Carcinoma ◽  
Preclinical Models

Serum SCC-Ag in Head and Neck Squamous Cell Carcinoma

1990 ◽  
Vol 5 (3) ◽  
pp. 118-120 ◽  
Author(s):  
F. Palermo ◽  
A. Carniato ◽  
A. Fede ◽  
F. Boccaletto ◽  
C. Marchiori
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Serum Levels ◽  
Neck Squamous Cell Carcinoma ◽  
Control Group ◽  
Double Antibody ◽  
Combined Evaluation

We estimated the serum levels of SCC-Ag, CEA and TPA in 69 patients with head or neck neoplasia and 31 healthy patients using a radioimmunometric method (double antibody). SCC-Ag concentrations were significantly increased in 43.4% cancer patients with respect to the cut-off point value (1.7 ng/ml) of the control group, and the specificity was 96.7%. The data varied according to the evolutive phase of disease. Since the combined evaluation of SCC-Ag, TPA and CEA serum levels increased the sensitivity, that was 71.0%, we thought it opportune to use all these markers in the tumoral pahtology taken into consideration.

Serum levels of interleukins 4 and 10 in head and neck squamous cell carcinoma

2011 ◽  
Vol 126 (2) ◽  
pp. 175-179 ◽  
Author(s):  
Z Mojtahedi ◽  
B Khademi ◽  
A Yehya ◽  
A Talebi ◽  
M J Fattahi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Tumour Progression ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Neck Squamous Cell Carcinoma ◽  
Interleukin 4 ◽  
Tumour Stage

AbstractObjective:There is currently controversy over the association between serum interleukin-4 and -10 levels and head and neck squamous cell carcinoma in patients of different ethnicity. This study aimed to investigate serum levels of these cytokines in Iranian patients with this pathology, and to analyse correlations with tumour location and tumour stage at diagnosis.Design:Serum cytokines levels were quantified using commercial enzyme-linked immunosorbent assays.Subjects:Study groups comprised 93 untreated patients and 53 healthy donors.Results:Serum interleukin-4 levels were significantly increased in patients compared with controls (p < 0.000), but were not significantly associated with tumour stage. Serum interleukin-10 levels were not raised in patients, nor associated with tumour stage.Conclusion:Serum levels of interleukin-4, but not -10, were increased in Iranian head and neck squamous cell carcinoma patients. These data do not support an association of these cytokines with tumour progression; this is consistent with previous findings.

scholarly journals CT Perfusion Can Predict Overexpression of CXCL8 (Interleukin-8) in Head and Neck Squamous Cell Carcinoma

2013 ◽  
Vol 34 (12) ◽  
pp. 2338-2342 ◽  
Author(s):  
S.Y. Jo ◽  
P.I. Wang ◽  
J.E. Nör ◽  
E.L. Bellile ◽  
Z. Zhang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Ct Perfusion ◽  
Interleukin 8 ◽  
Neck Squamous Cell Carcinoma

Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma

1997 ◽  
Vol 174 (5) ◽  
pp. 507-512 ◽  
Author(s):  
Bryan L. Richards ◽  
Roselle J. Eisma ◽  
Jeffrey D. Spiro ◽  
Richard L. Lindquist ◽  
Donald L. Kreutzer
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Interleukin 8 ◽  
Neck Squamous Cell Carcinoma

Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma

2003 ◽  
Vol 117 (3) ◽  
pp. 190-194 ◽  
Author(s):  
Yan Fei Deng ◽  
Ping Chen ◽  
Yong Zhi Lin ◽  
Jia Zhen Le ◽  
Xiao Li Wu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Primary Tumour ◽  
Serum Levels ◽  
Neck Squamous Cell Carcinoma ◽  
Close Monitoring ◽  
Healthy Controls ◽  
Benign Tumours

This paper attempts to evaluate the clinical usefulness of CYFRA 21-1 as a serum tumour marker in patients with head and neck squamous cell carcinoma (HNSCC).The serum concentration of CYFRA 21-1 was measured utilizing a new electrochemiluminescent immunoassay (ECLIA) in 142 patients with HNSCC before and after treatment, 68 patients with benign tumours of the head and neck, and 50 healthy controls.Serum levels of CYFRA 21-1 in patients with HNSCC were significantly higher than those of benign tumours and healthy controls (p < 0.001). The diagnostic sensitivity and specificity of CYFRA 21-1 for HNSCC were 62 per cent and 100 per cent, respectively. The positive rates of CYFRA 21-1 increased with progression of HNSCC, serum CYFRA 21-1 levels were related to the tumour stage expressed by primary tumour (T) and nodal status (N) (p < 0.001), but not related to patient age, gender, smoking and drinking habit, or histopathological grade (p > 0.05). Post-treatment levels of CYFRA 21-1 in HNSCC decreased significantly (p < 0.001). Among 38 patients with clinical or radiological evidence of a recurrence during follow-up, 78.9 per cent (30 of 38) showed an increase in CYFRA 21-1.The analytical ECLIA performance for serum CYFRA 21-1 provides a new means of clinical assessment for HNSCC. The results of ECLIA suggest that the serum marker CYFRA 21-1 is valuable not only for diagnosis but also for close monitoring of patients with HNSCC.

Sign in / Sign up

Export Citation Format

Share Document